West Pharmaceutical Services Reports Director and Officer Changes
Ticker: WST · Form: 8-K · Filed: Oct 7, 2024 · CIK: 105770
Sentiment: neutral
Topics: management-change, compensation, governance
TL;DR
WEST board/exec comp changes filed. Watch for new leadership/pay structures.
AI Summary
On October 1, 2024, West Pharmaceutical Services, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated, though specific details on new appointments or compensation figures are not provided in this excerpt.
Why It Matters
Changes in a company's board of directors and executive compensation can signal strategic shifts or governance updates that may impact future performance and shareholder value.
Risk Assessment
Risk Level: medium — Changes in executive leadership and compensation can sometimes precede significant strategic shifts or indicate internal challenges.
Key Numbers
- 1-08036 — SEC File Number (Identifies the company's filing history with the SEC.)
- 23-1210010 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- WEST PHARMACEUTICAL SERVICES, INC. (company) — Registrant
- Pennsylvania (location) — State of incorporation
- 530 Herman O. West Drive, Exton, PA 19341-1147 (address) — Principal executive offices
FAQ
What specific changes were made to the board of directors?
The filing indicates changes in directors but does not specify the names of departing or newly appointed directors in the provided excerpt.
Were there any new appointments to executive officer positions?
The filing mentions 'Appointment of Certain Officers' as an item reported, but specific details on who was appointed are not included in this excerpt.
What are the details of the new compensatory arrangements?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific terms and amounts of these arrangements are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated October 1, 2024.
What is the company's primary business as indicated by its SIC code?
The company's Standard Industrial Classification (SIC) code is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-10-07 16:04:41
Key Financial Figures
- $0.25 — ich registered Common Stock, par value $0.25 per share WST New York Stock Exchange
Filing Documents
- wst-20241001.htm (8-K) — 31KB
- wst-20241001_g1.jpg (GRAPHIC) — 17KB
- 0000105770-24-000071.txt ( ) — 200KB
- wst-20241001.xsd (EX-101.SCH) — 2KB
- wst-20241001_lab.xml (EX-101.LAB) — 21KB
- wst-20241001_pre.xml (EX-101.PRE) — 12KB
- wst-20241001_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit No. Description 104 The cover page from the Company's Current Report on Form 8-K, dated October 1, 2024, formatted in Inline XBRL. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 7, 2024 WEST PHARMACEUTICAL SERVICES, INC. By: /s/ Kimberly Banks MacKay Kimberly Banks MacKay Senior Vice President, General Counsel and Secretary 3 EXHIBIT INDEX Exhibit No. Description 104 The cover page from the Company's Current Report on Form 8-K, dated October 1, 2024, formatted in Inline XBRL. 4